Once-weekly subcutaneous semaglutide use I GLP-1 naïve patients with type 2 diabetes in North Macedonia: real world data from the MIRAGE study.
Date Issued
2023-04
Author(s)
Chekorova Mitreva, Biljana
Abstract
Safety and efficacy of once weekly (OW) subcutaneous (s.c.) semaglutide in T2D patients has been established in phase 3 clinical trials. In North Macedonia, no real-world evidence studies were conducted so far to assess the use of once weekly (OW) semaglutide in routine clinical practice.
